KRT88P and liver disorder: Moreover, the level of the serum hepatitis B core antigen (HBcAg) antibody (anti-HBc) was to be found positively correlated with HBV-induced liver disease or inflammation (13, 14) and predicted the therapeutic efficacy of peginterferon (Peg-IFN) and nucleos(t)ide analogs (NAs) in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients (15–17).